1. Home
  2. DPRO vs CRBP Comparison

DPRO vs CRBP Comparison

Compare DPRO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Draganfly Inc.

DPRO

Draganfly Inc.

HOLD

Current Price

$7.19

Market Cap

169.4M

Sector

Industrials

ML Signal

HOLD

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$8.07

Market Cap

170.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DPRO
CRBP
Founded
1998
2009
Country
Canada
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
169.4M
170.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DPRO
CRBP
Price
$7.19
$8.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$15.67
$50.29
AVG Volume (30 Days)
1.5M
493.9K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,335,758.00
N/A
Revenue This Year
$50.81
N/A
Revenue Next Year
$149.77
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
26.74
N/A
52 Week Low
$1.63
$4.64
52 Week High
$14.40
$20.56

Technical Indicators

Market Signals
Indicator
DPRO
CRBP
Relative Strength Index (RSI) 48.92 30.34
Support Level $6.56 $7.97
Resistance Level $8.36 $8.54
Average True Range (ATR) 0.64 0.46
MACD 0.03 0.06
Stochastic Oscillator 47.85 6.47

Price Performance

Historical Comparison
DPRO
CRBP

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: